Meta-analysis comparing the efficacy of anti-EGFR monoclonal antibody therapy between KRAS G13D and other KRAS mutant metastatic colorectal cancer tumours
- 1 March 2016
- journal article
- research article
- Published by Elsevier in European Journal of Cancer
- Vol. 55, 122-130
Abstract
No abstract availableKeywords
This publication has 28 references indexed in Scilit:
- KRAS p.G13D mutations are associated with sensitivity to anti-EGFR antibody treatment in colorectal cancer cell linesJournal of Cancer Research and Clinical Oncology, 2012
- Specific Mutations inKRASCodons 12 and 13, and Patient Prognosis in 1075BRAFWild-Type Colorectal CancersClinical Cancer Research, 2012
- Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancerNature, 2012
- Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trialThe Lancet, 2011
- Association of KRAS p.G13D Mutation With Outcome in Patients With Chemotherapy-Refractory Metastatic Colorectal Cancer Treated With CetuximabJAMA, 2010
- Assessing and reporting heterogeneity in treatment effects in clinical trials: a proposalTrials, 2010
- Activating K-Ras mutations outwith ‘hotspot’ codons in sporadic colorectal tumours – implications for personalised cancer medicineBritish Journal of Cancer, 2010
- Use of Archived Specimens in Evaluation of Prognostic and Predictive BiomarkersJNCI: Journal of the National Cancer Institute, 2009
- Overexpressed vs mutated Kras in murine fibroblasts: a molecular phenotyping studyBritish Journal of Cancer, 2009
- PTEN loss of expression predicts cetuximab efficacy in metastatic colorectal cancer patientsBritish Journal of Cancer, 2007